1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNIAID Research Opportunity Announcements - Pathogen Biology is sponsored by National Institute of Allergy and Infectious Diseases. Funds studies on viral pathogenesis including EBV-host interactions relevant to autoimmune triggers like MS.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Two Research Areas Comprise NIAID’s 2026 Omnibus Contract Solicitation | NIAID: National Institute of Allergy and Infectious Diseases Resources for Researchers Division of Intramural Research Labs Research at Vaccine Research Center Intramural Scientist & Clinician Directory Research Rules & Policies Allergy, Immunology & Transplantation Resources for Researchers Antimicrobial (Drug) Resistance Antimicrobial Resistance Threats Information for Researchers Risk Factors & Prevention Research Immune Tolerance Processes Disease-Specific Research Information for Researchers Autoimmune Lymphoproliferative Syndrome (ALPS) Basic & Preclinical Research Information for Researchers Information for Researchers Shiga Toxin-Producing E.
coli (STEC) Researching Ebola in Africa Information for Researchers Information for Researchers Why Food Allergy is a Priority for NIAID Characterizing Food Allergy & Addressing Related Disorders Information for Researchers Diagnosis & Management Guidelines Disease-Specific Research Information for Researchers Genomics & Advanced Technologies Pathogen-Based Initiatives Information for Researchers Information for Researchers Group A Streptococcal Infections Disease-Specific Research Information for Researchers Overview of the Immune System Features of an Immune Response Information for Researchers Information for Researchers Leprosy (Hansen's Disease) How NIAID is Addressing Lyme Disease Information for Researchers Parasite, Mosquito & Human Host Prevention, Treatment & Control Strategies Strategic Partnerships & Research Capacity Information for Researchers Information for Researchers Neglected Tropical Diseases Information for Researchers Translational & Clinical Research Cross-cutting Preparedness Molecular & Genetic Research Primary Immune Deficiency Diseases (PIDDs) Information for Researchers Animal Prion Diseases and Humans Information for Researchers Respiratory Syncytial Virus (RSV) Schistosomiasis (Bilharzia) Research in Endemic Regions Sexually Transmitted Infections (STIs) NIAID's Research Approach Information for Researchers Disease-Specific Research Information for Researchers Information for Researchers Disease-Specific Vaccines Information for Researchers Translational & Clinical Research Information for Researchers Biology, Genetics & Clinical Research NIAID's Approach to Women's Health Research Sex-Specific Health Challenges Facing Women Biennial Report (FY 2019-2020) Information for Researchers Why NIAID Is Researching Zika Virus Information for Researchers Find a Funding Opportunity Opportunities & Announcements NIAID Research Priorities Plan Your Budget & Personnel Additional Application Elements Research with Special Considerations After You Submit an Application Funding Policies and Considerations Understand the Review Process Respond to Pre-Award Requests Negotiation & Initial Award Become a Healthy Volunteer Participant's Guide to Clinical Trials HIV and Emerging Infectious Diseases Laboratory of Infectious Diseases Primary Immune Deficiency Clinic Vaccine Research Center Clinical Studies Fill Out the Volunteer Form Q&A: Vaccine Clinical Studies Vaccine Clinical Studies Safeguards Clinical Trial Publications NIAID-Funded Research News Division of Allergy, Immunology, and Transplantation Division of Microbiology and Infectious Diseases Division of Extramural Activities Division of Clinical Research Division of Intramural Research Dr. Joseph J.
Kinyoun: Father of the NIH Dr. Joseph Kinyoun The Indispensable Forgotten Man Dr. Joseph Kinyoun: Selected Bibliography NIAID 60th Anniversary Timeline Research Training at NIAID Campuses Grant Programs that NIAID Funds AIDS Research Advisory Committee AIDS Vaccine Research Subcommittee Board of Scientific Counselors Members Advisory and Peer Review Committees Autoimmune Diseases Committee Website Policies and Notices External Link Icon and Disclaimers Freedom of Information Act (FOIA) Voluntarily Submitted Information Two Research Areas Comprise NIAID’s 2026 Omnibus Contract Solicitation Funding News Editions: January 15, 2025 See more articles in this edition NIAID’s Division of Microbiology and Infectious Diseases (DMID) is soliciting proposals as part of the 2026 NIAID Omnibus Broad Agency Announcement (BAA).
DMID will use this BAA to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for biodefense and emerging infectious diseases. The 2026 BAA covers two distinct Research Areas: 001 and 002. Applicants may respond to either one or both Research Areas.
See descriptions of each below. For each research area and topic, if applicable, make sure to submit separate technical and business proposals designed to meet the objectives described. Performance Period: Not to exceed 5 years (base plus options).
Proposal Submission: Online through the electronic Contract Proposal Submission (eCPS) website . Research Area 001 – Development of Candidate Therapeutics, Vaccines, and In Vitro Diagnostics for Antimicrobial-Resistant (AMR) Bacterial or Fungal Pathogens Description: For Research Area 001, there are three separate topics.
Offerors may submit a proposal in response to Topics A, B, and/or C: Topic A: Therapeutics for AMR Bacterial or Fungal Pathogens The objective of Topic A is to develop new therapeutic products against severe infections and/or drug-resistant strains of the following bacterial and fungal pathogens: a. Pseudomonas aeruginosa , and/or Acinetobacter baumannii ; OR b. Candida auris, Cryptococcus spp.
, Aspergillus fumigatus , and/or Mucorales Topic B: Vaccines for AMR Bacterial Pathogens The objective of Topic B is to protect human health and well-being by advancing vaccine candidates for the following ESKAPE bacterial pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter species.
Topic C: In Vitro Diagnostics for AMR Fungal Pathogens The objective of Topic C is to develop innovative platform technologies to speed the identification of infection from among a broad panel of fungi and to profile the phenotypic antifungal susceptibility.
This emphasis aligns with NIAID’s goal of addressing persistent challenges in adequate clinical management associated with mycological infections and alleviating the burden of antifungal resistance.
Research Area 002 – Development of Direct Acting Antivirals (DAA) for Viral Families of Pandemic Potential Description: This Research Area aims to develop safe and effective antivirals to combat viruses of pandemic potential, as well as to build sustainable platforms for targeted drug discovery and the development of a robust pipeline of candidates.
Proposals submitted as part of this research area must focus on antivirals that: Directly modify viral target function (not through the modulation of the host responses); AND Act by reducing viral burden in early stages of disease; AND Act against viruses of pandemic potential (i.e., Bunyaviridae, Coronaviridae, Filoviridae, Flaviviridae, Orthopoxviridae, Paramyxoviridae, Picornaviridae, and Togaviridae ); AND Are new chemical entities limited to small molecules (e.g., natural products, nucleosides, or peptides of </= 40 amino acids) and nanobody conjugates/fusion products that are directly acting on viral targets and functions (not through the modulation of the host responses); AND Have safety profiles and suitable routes of administration for broad outpatient use.
Number of Awards, Total Cost: NIAID estimates that one or two awards may be issued for Research Area 001 for a total cost of up to $8. 5 million for the non-severable base period across all contracts (direct and indirect costs combined). Three to four awards may be issued for Research Area 002 for a total cost of up to $20 million for the non-severable base period across all contracts (direct and indirect costs combined).
Due Dates: for Research Area 001, February 21, 2025, by 3 p. m. Eastern Time; for Research Area 002, January 21, 2025, by 3 p.
m. Eastern Time. Find complete details in the solicitation itself as well as any amendments issued since this article was published.
Direct inquiries to Swee L. Teo, Contracting Officer, at teosl@niaid. nih.
gov or 240-669-5173. Content last reviewed on January 15, 2025
According to the current listing, eligibility includes: Universities, academic institutions. Confirm the full requirements in the official notice before applying.
The current listing shows $500,000+. Verify award ceilings, matching requirements, and allowable costs in the official notice.
NIAID Research Opportunity Announcements - Pathogen Biology is funded by National Institute of Allergy and Infectious Diseases. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.